Surrozen Inc Ordinary Shares SRZN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SRZN is a good fit for your portfolio.
News
-
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
-
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
-
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
Trading Information
- Previous Close Price
- $8.61
- Day Range
- $8.14–8.98
- 52-Week Range
- $4.50–16.19
- Bid/Ask
- $8.50 / $8.98
- Market Cap
- $28.72 Mil
- Volume/Avg
- 11,126 / 17,639
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.01%
Company Profile
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 42
- Website
- https://www.surrozen.com
Valuation
Metric
|
SRZN
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.49 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
SRZN
|
---|---|
Quick Ratio | 5.34 |
Current Ratio | 5.75 |
Interest Coverage | — |
Quick Ratio
SRZN
Profitability
Metric
|
SRZN
|
---|---|
Return on Assets (Normalized) | −38.13% |
Return on Equity (Normalized) | −44.86% |
Return on Invested Capital (Normalized) | −44.91% |
Return on Assets
SRZN
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cqwtgmqqt | Bgpb | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fbxgpmnr | Kvvszfk | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fwnnrntw | Lcqcp | $97.8 Bil | |
MRNA
| Moderna Inc | Jmlrvkzf | Pflx | $41.3 Bil | |
ARGX
| argenx SE ADR | Bmsccpy | Jvw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Dnzbpthl | Lrdh | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rrjlgwnbr | Pfvmhwp | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Sslgzbpw | Fkqbdn | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jpzmhbgj | Qddjpxj | $12.5 Bil | |
INCY
| Incyte Corp | Ssccbkdc | Nnyty | $11.6 Bil |